Duke University

Regeneron Pharmaceuticals, Inc.

Children's Medical Center Corporation

Albert Einstein College of Medicine

Garnett Kelsoe

Barton F Haynes

Andrew J Murphy

George D Yancopoulos

Lynn Macdonald

Cagan Gurer

John R McWhirter

Aris I Baras

Karolina Meagher

Israel Lowy

Stephen C Harrison

Thomas B Kepler

Masayuki Kuraoka

Betsy C Herold

M Anthony Moody

William R Jacobs

Clare Burn

Laurent Verkoczy

Matt T Holl

Provided are antibodies and antigen-binding fragments which bind to herpes simplex virus-2 (HSV-2), methods of use employing the antibodies and/or antigen-binding fragments, and pharmaceutical compositions comprising the antibodies and/or antigen-binding fragments.

Monoclonal antibodies for prevention and treatment of herpes simplex viral infections

The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol.

Methods to identify prime and boost immunogens for use in a B cell lineage-based vaccination protocol

Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.

B cell lineage based immunogen design with humanized animals

GP120 immunogens and methods inducing neutralizing antibodies to human immunodeficiency virus

The present invention relates, in general, to human immunodeficiency virus (HIV-1) and, in particular, to a method of enhancing an immune response to an HIV-1 immunogen, and to compounds and compositions suitable for use in such a method.

Adjuvant

Growing community of inventors

Durham, NC, United States of America

Garnett Kelsoe